# Immune Response in Patients Who Have Undergone Vaccine Therapy for Stage III or Stage IV Breast Cancer That Overexpresses HER2

> **NCT00363012** · NA · COMPLETED · sponsor: **University of Washington** · enrollment: 56 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** HER-2/neu intracellular domain protein
- **OTHER:** flow cytometry
- **OTHER:** immunohistochemistry staining method
- **PROCEDURE:** biopsy
- **OTHER:** Sterile water placement

## Key facts

- **NCT ID:** NCT00363012
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2017-04-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00363012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00363012, "Immune Response in Patients Who Have Undergone Vaccine Therapy for Stage III or Stage IV Breast Cancer That Overexpresses HER2". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00363012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*